Project cooperationUpdated on 28 May 2025
OKO | Ophthalmic Drug Delivery
About
At IDE Group we believe effective therapies and efficient treatments should never be compromised by their delivery method. In ocular drug delivery, injection devices designed for other applications lead to complex injection procedures that can diminish both therapeutic outcomes and workflow efficiency.
IDE has developed the revolutionary ophthalmic auto injector: OKO. By redefining the standard of ocular injections, OKO both enhances current therapeutics and paves the way for novel drugs and treatment modalities.
With unprecedented dose accuracy, a reduction in procedural complexity, error prevention features, and improved patient experience, OKO sets a new benchmark for safe, cost-effective, fast and scalable ophthalmic drug delivery in a single purpose-built device. OKO delivers the right drug, the right dose, to the right ocular compartment, transforming a complex procedure into single action injection.
OKO’s first clinical application, intravitreal injections, is now in development. To learn more about its use with your treatment visit https://ide.group/projects/ophthalmic-drug-delivery/
Stage
- Execution
Type
- Research
- Sales/Distribution
- Financing
Organisation
Rotterdam, Netherlands
Similar opportunities
Service
- Others
- Medtech
- Coaching
- Consulting
- Development
- Manufacturing
Renate Boekee - Hulst
Project Manager and Senior Product Developer at IDE Group
Rotterdam, Netherlands
Service
Efficient global sourcing & hospital supply solutions
- Medtech
- Development
Chris Zollner
Founder, CEO and President at ZOLMED International Holding B.V.
Maastricht, Netherlands
Project cooperation
Digital Infrastructure for Medical-Legal Partnerships (MLPs)
- Research
- Execution
- Technical
- Financing
Julian Rivera
Founder, SynergyFoundry; Professor of Practice, AI & Health Law; Director, Texas eHealth Alliance at Texas eHealth Alliance (TeHA)
Austin, United States